However, a phase II study failed to prove that the proportion of patients who were progression‐free at 18 weeks was higher in advanced or metastatic endometrial cancer with FGFR mutations than in FGFR‐non‐mutated endometrial cancer when treated by dovitinib, a TK inhibitor (TKI) of FGFRs, VEGFRs, PDGFR‐beta and c‐KIT after first‐line chemotherapy.63 Here, KIT is linked to endometrial cancer.